SCHEMBL5485068

SCHEMBL5485068

O=C1C=C(c2ccccc2)C(=O)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 1.00
PTPN1 P18031 4/20 0.70
PTPRC P08575 3/20 0.70
CDC25B P30305 3/20 0.70
PTPRF P10586 1/20 0.70
ALDH1A1 P00352 2/20 0.52
LMNA P02545 2/20 0.52
MAPT P10636 2/20 0.52
MAPK1 P28482 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
IDO1 P14902 2/20 0.52
CDC25A P30304 2/20 0.52
MAOA P21397 2/20 0.52
MAOB P27338 2/20 0.52
MEN1 O00255 1/20 0.52
PLIN1 O60240 1/20 0.52
NR1I2 O75469 1/20 0.52
USP2 O75604 1/20 0.52
GSR P00390 1/20 0.52
TP53 P04637 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29673492 1.00 BACE1 (1.00) BACE1PTPN1PTPRCCDC25BPTPRF
Methylamine SCHEMBL3277347 0.94 BACE1 (0.89) BACE1PTPN1PTPRCCDC25BPTPRF
SCHEMBL5139479 0.86 PTPN1 (0.76) BACE1PTPN1PTPRCCDC25BPTPRF
SCHEMBL30433091 0.86 PTPN1 (0.76) BACE1PTPN1PTPRCCDC25BPTPRF
SCHEMBL6555840 0.86 BACE1 (0.75) BACE1PTPN1PTPRCCDC25BPTPRF
SCHEMBL25834756 0.86 BACE1 (0.75) BACE1PTPN1PTPRCCDC25BPTPRF
SCHEMBL11048150 0.84 BACE1 (0.72) BACE1PTPN1PTPRCCDC25BPTPRF
SCHEMBL13020950 0.84 BACE1 (0.72) BACE1PTPN1PTPRCCDC25BPTPRF
SCHEMBL312389 0.84 BACE1 (1.00) BACE1PTPN1PTPRCCDC25BPTPRF
SCHEMBL28556962 0.84 BACE1 (0.72) BACE1PTPN1PTPRCCDC25BPTPRF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118176293-A SIRPalpha-deficient macrophages for the treatment of cancer 佐治亚州立大学研究基金会公司 2024-06-11 CN claimed
US-20230220342-A1 SIRPa Deficient Macrophages for Treating Cancer NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2023-07-13 US claimed
WO-2023076813-A1 SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2023-05-04 WO claimed
CN-115803092-A SIRP alpha deficient macrophages for the treatment of cancer 乔治亚州立大学研究基金公司 2023-03-14 CN claimed
EP-4139003-A1 SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER Georgia State University Research Foundation, Inc. (US) 2023-03-01 EP claimed
CN-114805398-A Preparation method of ecteinascidin compound 江苏恒瑞医药股份有限公司 2022-07-29 CN claimed
WO-2021217038-A1 SIRPα DEFICIENT MACROPHAGES FOR TREATING CANCER GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2021-10-28 WO claimed
US-4460674-A GALLIC ACID DERIVATIVES AND NAPOHTHOQUINONES KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1984-07-17 US claimed
US-6444385-B1 None US disclosed
US-20260149060-A1 Devices, Systems, and Methods for Rejuvenating Energy Devices Sonocharge Energy, Inc (US) 2026-05-28 US disclosed
US-20250333698-A1 SIRPa DEFICIENT MACROPHAGES FOR TREATING CANCER UNIV GEORGIA STATE RES FOUND (US) 2025-10-30 US disclosed
CN-119528710-A 2, 3-Disubstituted naphthoquinone compound, application and preparation method thereof 中国农业科学院兰州畜牧与兽药研究所 2025-02-28 CN disclosed
EP-4423251-A1 SIRP ALPHA DEFICIENT MACROPHAGES FOR TREATING CANCER Georgia State University Research Foundation, Inc. (US) 2024-09-04 EP disclosed
CN-118176293-A SIRPalpha-deficient macrophages for the treatment of cancer 佐治亚州立大学研究基金会公司 2024-06-11 CN disclosed
US-4757124-A Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments SHIN-ETSU CHEMICAL CO., LTD. (JP) 1988-07-12 US disclosed
US-4752547-A RECORDING LAYER CONTAINS REDUCING AGENT, LEWIS BASE COMPLEX, AND REDUCIBLE DYE FORMING COMPOUND EASTMAN KODAK COMPANY (US) 1988-06-21 US disclosed
US-4727008-A MULTILAYER-IMAGEWISE EXPOSURE TO ELECTRICAL CHARGES OF DIFFERENT POLARITIES TO GIVE DEVELOPABLE IMAGES EASTMAN KODAK COMPANY (US) 1988-02-23 US disclosed
EP-0172427-A2 Process for production of vinyl chloride polymer Shin-Etsu Chemical Co., Ltd. (JP) 1986-02-26 EP disclosed
EP-0150831-A2 Naphthalene anti-psoriatic agents SYNTEX (U.S.A.) INC. (US) 1985-08-07 EP disclosed
US-4460674-A GALLIC ACID DERIVATIVES AND NAPOHTHOQUINONES KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1984-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260149060-A1 Devices, Systems, and Methods for Rejuvenating Energy Devices TERT, WRN, SIRT3 BACE1 3146/4885PTPN1 3641/4885PTPRC 2788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.